Sign up
Pharma Capital
Markets

AMD, Intel, IBM, Finisar, Exact Sciences Corporation - AFTER HOURS

'Meltdown' and 'Spectre' are two related, side-channel attacks against modern CPU microprocessors; AMD it not susceptible to Meltdown but it is to Spectre. Intel chips are susceptible to both
Central processing unit
Chips are down ... AMD's stock fell 3.5% in after-hours

Apparently computer chips made by Advanced Micro Devices Inc (NASDAQ:AMD) are not practically immune to the Spectre security flaw that affects Intel chips.

In an interview with Yahoo Finance, the chip-maker's chief executive officer Lisa Su said that the company's chips were not susceptible to the Meltdown flaw, which affects Intel chips, but they do have the Spectre security flaw.

The company's shares fell 3.5% in after-hours trading. Intel Corporation's (NASDAQ:INTC) stock edged up 0.3%.

Elsewhere in the technology sector communication equipment maker Finisar Corporation (NASDAQ:FNSR) was wanted after it named former Broadcom executive Michael Hurlston as its new chief executive officer.

Hurlston will replace co-founder Jerry Rawls, who announced his retirement.

In other technology board room news, investors in International Business Machines Corp (NYSE:IBM) shrugged off news that chief financial officer Martin Schroeter is to quit the role and become senior vice president of global markets.

The stock was modestly higher in screen-based trading.

Exact Sciences Corporation (NASDAQ:EXAS) had an evening stumble after increasing the size of its fund-raising from US$500mln to US$600mln.

The molecular diagnostics company priced its underwritten public offering of 1.0% convertible senior notes due 2025; the initial conversion rate will be 13.2569 shares of common stock per US$1,000 of notes, which is equivalent to an initial conversion price of around US$75.43 per share. 

The shares were down US$3.16 at US$51.90 in electronic trading.

John-H.jpg

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.